Citations

Mayo Clinic

Showing 10 of 108551 citations.

Images in Immunotherapy and Precision Oncology: Advanced Basal Cell Carcinoma
Deshpande, Anagha , Muñoz, Javier , Kurzrock, Razelle

Journal of Immunotherapy and Precision Oncology | March 4, 2024 | Volume: 7 | Issue: 3 | Pages: 201-204

10.36401/jipo-23-47 | PMID 39219994 Get It

ABSTRACT A 62-year-old man presented with a slowly growing, painless lesion on his face. This eventually led to a progressive left-eye vision lesion, and the patient was subsequently diagnosed with advanced basal cell carcinoma (BCC). Of note, BCC involving cranial nerves is extremely rare, making this case unique and important to highlight. Standard treatment options for BCC involve surgery, radiation, or platinum-based chemotherapy. However, targeted therapies such as sonidegib and vismodegib – sonic hedgehog pathway inhibitors – have emerged that have been approved for treating BCC, as have anti-PD1 immunotherapies, such as cemiplimab, with their success likely based on the high tumor mutational burden seen in some of these tumors. Epidermal growth factor receptor (EGFR) inhibitors also serve a role in treating this condition as well. Molecular studies on metastatic/advanced BCC and other rare malignancies may inform treatment therapeutic decisions.
Coordinated Same- or Next-Day Radiosurgery and Cochlear Implantation for Vestibular Schwannoma
Macielak, Robert J. , Dornhoffer, James R. , Plitt, Aaron , Neff, Brian A., Driscoll, Colin L. W., Carlson, Matthew L. , Link, Michael J.

Otology & Neurotology | March 4, 2024 | Volume: 45 | Issue: 4 | Pages: 430-433

10.1097/mao.0000000000004149 | PMID 38437820 Get It

Abstract Objective To describe the experience and results from coordinated and closely scheduled radiosurgery and cochlear implantation (CI) in a vestibular schwannoma (VS) cohort. Patients Patients with VS who underwent radiosurgery followed by CI on the same or next day. Interventions Interventions included sequential radiosurgery and CI. Main Outcome Measures Tumor control defined by tumor growth on posttreatment surveillance and audiometric outcomes including consonant-nucleus-consonant words and AzBio sentences in quiet. Results In total, six patients were identified that met the inclusion criteria, with an age range of 38 to 69 years and tumor sizes ranging from 2.0 to 16.3 mm. All patients successfully underwent radiosurgery and CI on the same or immediately successive day. Postoperatively, all patients obtained open-set speech recognition. Consonant-nucleus-consonant word scores ranged from 40 to 88% correct, and AzBio scores ranged from 44 to 94% correct. During posttreatment magnetic resonance imaging surveillance, which ranged from 12 to 68 months, all tumors were noted to be adequately visualized, and no tumor progression was noted. Conclusion Coordinated radiosurgery and CI can be safely performed in patients with VS on the same or next day, serving to decrease burden on patients and increase access to this vital rehabilitative strategy.
Opioid Prescribing Patterns Following Lateral Skull Base Spontaneous Cerebrospinal Fluid Leak Repair
Ottinger, Allie M. , Raymond, Mallory , MILLER, EDITH, Meyer, Ted A., Raymond, Mallory J, Raymond, Mallory J , Miller, E. Marin

Otology & Neurotology | March 4, 2024 | Volume: 45 | Issue: 4 | Pages: e351-e358

10.1097/mao.0000000000004136 | PMID 38437814 Get It

Objective To characterize the opioid prescribing patterns for and requirements of patients undergoing repair of spontaneous cerebrospinal fluid (sCSF) leaks of the lateral skull base. Study Design Retrospective chart review. Setting Tertiary referral center. Patients Adults with lateral skull base sCSF leaks who underwent repairs between September 1, 2014, and December 31, 2020. Main Outcome Measure Mean morphine milligram equivalents (MMEs) of opioids dispensed to inpatients and prescribed at discharge, additional pain control medications dispensed, and outpatient additional opioid requests were compared between groups. Results Of 78 patients included, 46 (59%) underwent repair via a transmastoid (TM), 6 (7.7%) via a middle cranial fossa (MCF), and 26 (33.3%) via a combined TM–MCF approach. Inpatients received a mean of 21.3, 31.4, and 37.6 MMEs per day during admission for the TM, MCF, and combined TM–MCF approaches, respectively (p = 0.019, ηp2 = 0.101). Upon discharge, nearly all patients (n = 74, 94.9%) received opioids; 27.3, 32.5, and 37.6 MMEs per day were prescribed after the TM, MCF, and TM–MCF approaches, respectively (p = 0.015, ηp2 = 0.093). Five (6.4%) patients requested additional outpatient pain medication, after which three were prescribed 36.7 MMEs per day. Patients with idiopathic intracranial hypertension required significantly more inpatient MMEs than those without (41.5 versus 25.2, p = 0.02, d = 0.689), as did patients with a history of headaches (39.6 versus 23.6, p = 0.042, d = 0.684). Conclusions Patients undergoing sCSF leak repair via the MCF or TM–MCF approaches are prescribed more opioids postoperatively than patients undergoing the TM approach. Patients with a history of headaches or idiopathic intracranial hypertension might require more opioids postoperatively.
Abstract B098: Impact of dexamethasone on chemotherapy response in ovarian cancer
Venkatachalam, Annapoorna , McGehee, Cordelia D. , Finstuen-Magro, Sarah, Schneider, Paula A., Hurley, Rachel M. , Peterson, Kevin L. , Heinzen, Ethan P. , Hou, Xiaonon, Oberg, Ann L. , Weroha, Saravut J., Correia, Cristina , Finstuen-Magro, Sarah, Larson, Melissa C. , Kaufmann, Scott H.

Cancer Research | March 4, 2024 | Volume: 84 | Issue: 5_Supplement_2 | Pages: B098-B098

10.1158/1538-7445.ovarian23-b098 Get It

Abstract Background: Ovarian cancer ranks fifth in cancer deaths among women. The gold standard of care for advanced disease includes cytoreductive surgery along with adjuvant or neoadjuvant platinum/taxane-based chemotherapy. Although response to this treatment is high, chemotherapy-induced nausea and vomiting due to platinum agents and allergic reactions due to both agents are common. For nearly half a century, the glucocorticoid (GC) dexamethasone (DEX) has been administered as part of supportive care. However, there have periodically been questions about the possible deleterious effects of DEX on chemotherapy response, especially in solid tumors. Methods: Platinum-sensitive, glucocorticoid receptor (GRa) expressing ovarian cancer cells were exposed to DEX prior to chemotherapy and clonogenic survival was assessed. The effects of DEX on cell cycle and apoptosis were assessed by flow cytometry. Changes in the tumor cell transcriptome after acute DEX treatment were determined by RNA sequencing. Mice bearing orthotopic ovarian cancer patient-derived xenografts (PDXs) were treated with chemotherapy ± DEX to assess changes in chemotherapy response in vivo. Findings: DEX pre-treatment decreased platinum cytotoxicity in ovarian cancer cell lines in vitro and diminished platinum response in some PDXs analyzed for chemotherapy response ex vivo. RNA-seq analysis revealed changes in transcripts encoding proteins involved in platinum detoxification and TNFa pro-survival signaling. In ovarian cancer PDXs, DEX decreased platinum response in one model and had limited impact on both platinum and platinum/taxane chemotherapy in three distinct studies. Interpretation: DEX appears to modulate chemotherapy response in some settings in vitro and ex-vivo. The impact of DEX on chemotherapy response in vivo appears to be limited. However, further investigation of this question in vivo in non-immunosuppressed murine models appears warranted. Citation Format: Annapoorna Venkatachalam, Cristina Correia, Cordelia Mcgehee, Sarah Finstuen-Magro, Paula A. Schneider, Rachel Hurley, Kevin L. Peterson, Ethan Heinzen, Melissa C. Larson, Xiaonon Hou, Ann L. Oberg, Saravut Weroha, Scott H. Kaufmann. Impact of dexamethasone on chemotherapy response in ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2):Abstract nr B098.
Artificial intelligence in medicine: mitigating risks and maximizing benefits via quality assurance, quality control, and acceptance testing
Mahmood, Usman , Chan, Heang‐Ping , Drukker, Karen , Samala, Ravi K. , Vergara, Daniel , Petrick, Nicholas , Huo, Zhimin, Summers, Ronald M. , Cha, Kenny H, Grizzard, Kevin , Yoshida, Hiroyuki , Mazurchuk, Richard, Suzuki, Kenji , Armato, Samuel G. , Chan, Heang-Ping , Drukker, Karen , Samala, Ravi K , Vergara, Daniel , Petrick, Nicholas , Summers, Ronald M , Deserno, Thomas M , Shukla‐Dave, Amita , Chen, Quan , Greenspan, Hayit , Sahiner, Berkman , Cha, Kenny H, Tourassi, Georgia D. , Näppi, Janne J. , Regge, Daniele , Morra, Lia , Huisman, Henkjan , Hadjiiski, Lubomir M.

BJR|Artificial Intelligence | March 4, 2024 | Volume: 1 | Issue: 1 | Pages: No page available

10.1093/bjrai/ubae003 | PMID 38476957 Get It

Abstract The adoption of artificial intelligence (AI) tools in medicine poses challenges to existing clinical workflows. This commentary discusses the necessity of context-specific quality assurance (QA), emphasizing the need for robust QA measures with quality control (QC) procedures that encompass (1) acceptance testing (AT) before clinical use, (2) continuous QC monitoring, and (3) adequate user training. The discussion also covers essential components of AT and QA, illustrated with real-world examples. We also highlight what we see as the shared responsibility of manufacturers or vendors, regulators, healthcare systems, medical physicists, and clinicians to enact appropriate testing and oversight to ensure a safe and equitable transformation of medicine through AI.
Abstract B046: Lack of ER/PR expression and unresponsiveness to oral contraceptives in fallopian tube stem/progenitor cell states: reevaluating the mechanism of cancer prevention
Ritting, Megan L. , Bettencourt, M., Jalagam, Kinnera, Weroha, S. John , Aalam, Syed Mohammed Musheer , Jalagam, Kinnera, Kaufmann, Scott H. , Sherman, Mark E. , Bakkum‐Gamez, Jamie N. , Kannan, Nagarajan

Cancer Research | March 4, 2024 | Volume: 84 | Issue: 5_Supplement_2 | Pages: B046-B046

10.1158/1538-7445.ovarian23-b046 Get It

Abstract Objective: Prolonged use of oral contraceptives (OC) has been associated with a reduced risk of ovarian cancer, yet the underlying mechanism remains elusive. Long-lived self-renewing fallopian tube epithelial stem cells (SCs) capable of cilio-secretory differentiation are considered a potential cell-of-origin for ovarian cancers. Using innovative stem cell methodologies, our objective is to gain insights into the mechanism by which OC exert their protective action. Methods: This research is supported by Mayo Clinic’s clinically annotated regenerative fallopian tube biobank. RNA was isolated from the SC-enriched cell fraction and differentiated cilio-secretory organoids. Absolute mRNA copies of OC targets estrogen receptor-alpha (ESR1; ER) and progesterone receptor (PGR; PR) were determined using optimum RT-ddPCR assay. OC effects on SC-enriched growth in 2D was measured using live-cell imaging. Our primary tubal cells and organoids as well as public single-cell transcriptomics datasets were analyzed for ESR1/PGR expression across tubal cell states. Results: The panel of OCs tested exhibited no growth response in patient-derived cultures enriched with stem cells, and there was an absence of ESR1/PGR expression. Clonal organoid differentiation exhibited high ESR1 levels and lack of PGR, while growth factor cocktail-dependent PGR induction was achieved. Single-cell transcriptomics identified molecular signatures associated with ER/PR-positive OC sensor cells. Conclusions: Based on our findings, we propose a model wherein ER/PR-negative SC differentiate into ER/PR-positive OC-sensors and control SC development through paracrine signals. Our in-vitro conditions to differentiate SC into OC-sensors provide an opportunity to study complex paracrine signaling and explore targets for prevention of ovarian cancers. Citation Format: Megan Ritting, Syed Mohammed Musheer Aalam, Manny Bettencourt, Kinnera Jalagam, Scott Kaufmann, John Weroha, Mark Sherman, Jamie Bakkum-Gamez, Nagarajan Kannan. Lack of ER/PR expression and unresponsiveness to oral contraceptives in fallopian tube stem/progenitor cell states: reevaluating the mechanism of cancer prevention [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2):Abstract nr B046.
Burden of Ischemic and Hemorrhagic Stroke Across the US From 1990 to 2019
Renedo, Daniela , Aravkin, Aleksandr Y. , Bärnighausen, Till , Basu, Sanjay , Burkart, Katrin , Coberly, Kaleb, Criqui, Michael H. , Elgendy, Islam Y. , Gad, Mohamed M. , Hafezi‐Nejad, Nima , Kalani, Rizwan , Krishnamoorthy, Vijay , Lo, Warren , Miller, Ted R. , Misganaw, Awoke, Murray, Christopher J L , Natto, Zuhair S. , Ram, Pradhum , Roth, Gregory A. , Seylani, Allen, Shah, Nilay S. , Sharma, Purva, Song, Suhang , Wang, Cong , Xiao, Hong , Zand, Ramin , Falcone, Guido J. , Elgendy, Islam Y , Zand, Ramin , Acosta, Julián , Leasure, Audrey C. , Sharma, Richa , Krumholz, Harlan M. , Havenon, Adam de , Alahdab, Fares , Aryan, Zahra , Dai, Xiaochen , Desai, Rupak , Dharmaratne, Samath Dhamminda , Doshi, Rajkumar , Feigin, Valery L. , Filip, Irina , Ghozy, Sherief , Karaye, Ibraheem M. , Kısa, Adnan , Meštrović, Tomislav , Mokdad, Ali H. , Radfar, Amir , Sheikh, Aziz , Singh, Jasvinder A. , Sotoudeh, Houman , Vervoort, Dominique , Xu, Suowen , Sheth, Kevin N.

JAMA Neurology | March 4, 2024 | Volume: 81 | Issue: 4 | Pages: 394

10.1001/jamaneurol.2024.0190 | PMID 38436973 Get It

ImportanceStroke is a leading cause of death and disability in the US. Accurate and updated measures of stroke burden are needed to guide public health policies.ObjectiveTo present burden estimates of ischemic and hemorrhagic stroke in the US in 2019 and describe trends from 1990 to 2019 by age, sex, and geographic location.Design, Setting, and ParticipantsAn in-depth cross-sectional analysis of the 2019 Global Burden of Disease study was conducted. The setting included the time period of 1990 to 2019 in the US. The study encompassed estimates for various types of strokes, including all strokes, ischemic strokes, intracerebral hemorrhages (ICHs), and subarachnoid hemorrhages (SAHs). The 2019 Global Burden of Disease results were released on October 20, 2020.ExposuresIn this study, no particular exposure was specifically targeted.Main Outcomes and MeasuresThe primary focus of this analysis centered on both overall and age-standardized estimates, stroke incidence, prevalence, mortality, and DALYs per 100 000 individuals.ResultsIn 2019, the US recorded 7.09 million prevalent strokes (4.07 million women [57.4%]; 3.02 million men [42.6%]), with 5.87 million being ischemic strokes (82.7%). Prevalence also included 0.66 million ICHs and 0.85 million SAHs. Although the absolute numbers of stroke cases, mortality, and DALYs surged from 1990 to 2019, the age-standardized rates either declined or remained steady. Notably, hemorrhagic strokes manifested a substantial increase, especially in mortality, compared with ischemic strokes (incidence of ischemic stroke increased by 13% [95% uncertainty interval (UI), 14.2%-11.9%]; incidence of ICH increased by 39.8% [95% UI, 38.9%-39.7%]; incidence of SAH increased by 50.9% [95% UI, 49.2%-52.6%]). The downturn in stroke mortality plateaued in the recent decade. There was a discernible heterogeneity in stroke burden trends, with older adults (50-74 years) experiencing a decrease in incidence in coastal areas (decreases up to 3.9% in Vermont), in contrast to an uptick observed in younger demographics (15-49 years) in the South and Midwest US (with increases up to 8.4% in Minnesota).Conclusions and RelevanceIn this cross-sectional study, the declining age-standardized stroke rates over the past 3 decades suggest progress in managing stroke-related outcomes. However, the increasing absolute burden of stroke, coupled with a notable rise in hemorrhagic stroke, suggests an evolving and substantial public health challenge in the US. Moreover, the significant disparities in stroke burden trends across different age groups and geographic locations underscore the necessity for region- and demography-specific interventions and policies to effectively mitigate the multifaceted and escalating burden of stroke in the country.
Congenital Generalized Lipodystrophy in a Division 1 Female Sprinter
Schleich, Kevin , Novakofski, Kira D., Thomsen, Timothy W. , Woodroffe, Lisa , Slayman, Tyler , Schleich, Kevin T

Clinical Journal of Sport Medicine | March 4, 2024 | Volume: 34 | Issue: 4 | Pages: 396-399

10.1097/jsm.0000000000001214 | PMID 38914100 Get It

Abstract: A 21-year-old African American Division 1 female sprinter presented with 3-weeks history of right great toe and forefoot pain, fatigue, and a 30-day continuous menstrual cycle despite implanted etonogestrel (Nexplanon) inserted 3 years prior. An magnetic resonance imagine (MRI) identified likely stress fracture of the second metatarsal base with a diffusely low T1 signal indicating hyperactive red marrow. Due to persistent pain, a follow-up MRI was ordered 6 months later and indicated serous atrophy of the bone marrow, prompting a further metabolic workup notable for triglycerides exceeding 4000 mg/dL and a hemoglobin A1c of 10.9%. This case highlights the manifestation of a rare congenital lipodystrophy that initially presented as a relatively classic stress fracture and metrorrhagia in a female athlete.
Distinct presentation of melanoma in Black patients may inform strategies to improve outcomes
Steadman, Jessica A. , Glasgow, Amy E. , Neequaye, Nikki N., Hieken, Tina J. , Hieken, Tina J , Habermann, Elizabeth B.

Journal of Surgical Oncology | March 4, 2024 | Volume: 129 | Issue: 6 | Pages: 1041-1050

10.1002/jso.27608 | PMID 38436625 Get It

AbstractIntroductionMelanoma guidelines stem largely from data on non‐Hispanic White (NHW) patients. We aimed to identify features of melanoma within non‐Hispanic Black (NHB) patients to inform strategies for earlier detection and treatment.MethodsFrom 2004 to 2019 Surveillance, Epidemiology, and End Results (SEER) data, we identified nonmetastatic melanoma patients with known TN category and race. Kaplan–Meier cancer‐specific survival (CSS) estimates and multivariable Cox proportional hazard modeling analyses were performed.ResultsOf 492 597 patients, 1499 (0.3%) were NHB, who were younger (21% vs. 17% age <50) and more commonly female (54% vs. 41%) than NHW, both p < 0.0005. For NHBs, lower extremity was the most common site (52% vs. 15% for NHWs, p < 0.0001), T category was higher (55% Tis–T1 vs. 82%; 27% T3–T4 vs. 8%, p < 0.0001) and stage at presentation was higher (19% Stage III, vs. 6%, p < 0.0001). Within the NHB cohort, males were older, and more often node‐positive than females. Five‐year Stage III CSS was 42% for NHB males versus 71% for females, adjusting for age and clinical nodal status (hazard ratio 2.48).ConclusionsNHB melanoma patients presented with distinct tumor characteristics. NHB males with Stage III disease had inferior CSS. Focus on this high‐risk patient cohort to promote earlier detection and treatment may improve outcomes.
Abstract B002: Exploiting JAK/STAT signaling to inhibit highly advanced and resistant forms of ovarian cancer
Rodman, Esther , Emch, Michael , Bajaj, Archit, Hou, Xiaonan , Weroha, S. John , Hawse, John R. , Tang, Xiaojia , Kaufmann, Scott H. , Kalari, Krishna R.

Cancer Research | March 4, 2024 | Volume: 84 | Issue: 5_Supplement_2 | Pages: B002-B002

10.1158/1538-7445.ovarian23-b002 Get It

Abstract Ovarian cancer is the most fatal of all female reproductive cancers due to its late detection, aggressive nature, and propensity to develop resistance to current standards of care. Despite initial responses to first line platinum- and paclitaxel-based chemotherapies, &gt;70% of ovarian cancers recur with increasingly resistant disease. Targeted therapies, including PARP-inhibitors (PARPi) and VEGF-inhibitors, are being included in the front-line setting; and while they have improved progression-free survival in a subset of patients, they have thus far failed to improve overall survival in patients without specific genetic signatures. With the broad uptake of PARPi, PARPi-resistance is becoming common. Once resistance develops, nearly all patients die of their disease and there is an obvious need to elucidate the basis for chemotherapy- and PARPi-resistance and devise novel approaches to overcome resistance. Using a small molecule drug screen, we identified lestaurtinib, a known tyrosine kinase inhibitor as a potent inhibitor of treatment naive and highly advanced models of ovarian cancer. Lestaurtinib was originally developed to target FLT3, a protein not expressed in any ovarian cancer models we’ve tested. To identify lestaurtinib targets, we preformed phospho-proteomics in parallel with RNAseq and discovered the JAK/STAT signally pathway as a top hit. We confirmed that essential components of JAK/STAT signaling are constitutively activated in chemotherapy- and PARPi-resistant cells, suggesting that induction of this pathway may drive resistance. Importantly, we found that lestaurtinib-sensitive patient-derived-xenografts (PDXs) exhibited higher expression of multiple JAK/STAT signaling pathway members compared to PDXs that did not respond to lestaurtinib. Genetic knockdown of STAT1 and STAT3 via siRNA, or knockout via CRISPR/Cas9, resulted in significant growth inhibition of sensitive and resistant models, confirming their importance in maintaining cell viability and progression. Combining lestuartinib with standard-of-care cisplatin or olaparib, a PARPi, was shown to be synergistic in multiple models, indicating that pharmacological inhibition of JAK/STAT signaling has the potential to alleviate drug resistance. Finally, we assessed a panel of JAK/STAT inhibitors that interfere at various levels of the pathway and found profound differences in their ability to block STAT-phosphorylation and inhibit cell proliferation. Thus, it is critical to further define the mechanisms by which these drugs function to selectively suppress JAK/STAT signaling in order to elucidate specific nodes of the pathway that drive ovarian cancer progression. Ongoing studies are aimed at identifying the unique roles of STAT1 and STAT3, the specific contributions of their tyrosine and serine phosphorylation, and the relevance of up-/down-stream mediators of the JAK/STAT pathway on ovarian cancer cell growth with the goal of informing future clinical trials. Citation Format: Esther Rodman, Michael Emch, Archit Bajaj, Xiaojia Tang, Xiaonan Hou, Scott Kaufmann, Krishna Kalari, John Weroha, John Hawse. Exploiting JAK/STAT signaling to inhibit highly advanced and resistant forms of ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2):Abstract nr B002.